Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France LYON, France , Aug. 02, 2019 (GLOBE NEWSWIRE) --   Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the
View HTML
Toggle Summary ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 2019
LYON, France and CAMBRIDGE, Mass. , July 16, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019 . At the meeting, all resolutions for which management recommended a vote in favor, were
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2019
LYON, France , July 02, 2019 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC
LYON, France and CAMBRIDGE, Mass. , June 26, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Sep 9 - Sep 10, 2019

Morgan Stanley Global Healthcare Unplugged, New York

Summary Toggle Sep 17, 2019

Business Update and Financial Highlights for the 2nd quarter and first-half of 2019

Summary Toggle Sep 18, 2019 at 8:30 AM EDT

Erytech Pharma Second Quarter 2019 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top